Lexaria Bioscience Extends Material Transfer Agreement with Pharmaceutical Company
Lexaria Bioscience Corp. has extended its Material Transfer Agreement with an unnamed pharmaceutical company to evaluate its DehydraTECHTM technology in a pre-clinical setting. The agreement, originally signed in September 2024, will now run through April 30, 2026, allowing additional time for PharmaCO to review data from Lexaria’s Australian human clinical study. The extension maintains a temporary exclusive license and facilitates ongoing strategic discussions for potential collaboration in human clinical development.
Lexaria Bioscience Corp. has extended its Material Transfer Agreement with an unnamed pharmaceutical company (“PharmaCO”) to evaluate Lexaria’s DehydraTECHTM technology in a pre-clinical setting. The agreement, originally signed in September 2024, will now run through April 30, 2026, allowing PharmaCO additional time to review data from Lexaria’s Australian human clinical study. The extension maintains a temporary exclusive license and enables ongoing strategic discussions between the two companies as they consider further collaboration in human clinical development. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1100511) on November 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
